SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-003930
Filing Date
2023-02-23
Accepted
2023-02-23 07:11:06
Documents
15
Period of Report
2023-02-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kymr-20230223.htm   iXBRL 8-K 68389
2 EX-99.1 kymr-ex99_1.htm EX-99 197257
3 GRAPHIC img100385778_0.jpg GRAPHIC 4816
4 GRAPHIC img100385778_1.jpg GRAPHIC 4816
  Complete submission text file 0000950170-23-003930.txt   422370

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kymr-20230223.xsd EX-101.SCH 2474
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kymr-20230223_pre.xml EX-101.PRE 11544
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kymr-20230223_lab.xml EX-101.LAB 17744
9 EXTRACTED XBRL INSTANCE DOCUMENT kymr-20230223_htm.xml XML 4715
Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 23655909
SIC: 2836 Biological Products, (No Diagnostic Substances)